A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma

Pancreatic Adenocarcinoma Clinical Trial

Official title:

A Phase II Study of Peri-Operative NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05624918
• Other study ID #: BTCRC GI21-500
• Status: Recruiting
• Phase: Phase 2
• Start date: June 2024
• Est. completion date: August 2028

Study information

• Verified date: May 2024
• Source: Big Ten Cancer Research Consortium
• Contact: Ashish Manne, MD
• Phone: 614-293-9863
• Email: ashish.manne[@]osumc.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a single arm phase II study. All patients will receive 3 cycles of the treatment of nab-paclitaxel (Days 1, 8 and 15), gemcitabine (Days 1, 8 and 15), and TTFields (worn every day for at least 18 hours). Following the initial 3 cycles of gemcitabine/nab-paclitaxel/TTFields treatment, patients will undergo restaging by CT or MRI. Patients with stable disease or better will undergo surgery for resection within 8 weeks following completion of initial chemotherapy although enrolling sites are encouraged to perform resection within 4 weeks of Cycle 3 D15 of therapy. If resection yields R0 or R1, patients will begin an additional 3 cycles of gemcitabine/nab-paclitaxel/TTFields treatment within 8 weeks of surgery. Based on available literature, it is expected that a percentage of patients will not undergo resection either due to disease progression or due to toxicities/ complications of the neoadjuvant segment of therapy. These patients will be included in the evaluable patients for both co-primary endpoints as well as the secondary endpoints including ORR, adverse events, and OS.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 38
• Est. completion date: August 2028
• Est. primary completion date: August 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

-Written informed consent and HIPAA authorization for release of personal health information.

NOTE: HIPAA authorization may be included in the informed consent or obtained separately.

• Male or non-pregnant, non-lactating female age = 18 years at the time of consent.

• Karnofsky Performance Status (KPS) of =70% within 7 days prior to registration.

• Histological or cytological evidence of pancreatic adenocarcinoma.

• Patients must have resectable primary tumor per NCCN definitions version 2.2021 based on contrast-enhanced CT or MRI (CT or MRI without contrast as part of PET/CT or PET/MRI is NOT acceptable; CT or MRI with contrast as part of PET/CT or PET/MRI is acceptable) of the chest, abdomen, and pelvis, where resectable is defined as all of the following:

• No involvement of the celiac artery, common hepatic artery, and superior mesenteric artery (and, if present, replaced right hepatic artery).

• No involvement, or < 180° interface between tumor and vessel wall, of the portal vein and/or superior mesenteric vein; and patent portal vein/splenic vein confluence.

• No evidence of metastatic disease. NOTE: To minimize ineligible patients, an institutional checklist, identical to the one used by the central radiologist at the end of the study, will be mandated for completion by the enrolling site investigator or radiologist. The 6-point checklist will include visible pancreatic mass; measurable disease; absence of arterial interface; venous interface of less than or equal to 180°; patent portal-splenic confluence; and absence of metastatic disease, including lymphadenopathy outside the surgical basin.

• Measurable disease according to RECIST v1.1 for solid tumors within 28 days prior to registration.

• Patients must not have received prior surgery, radiation therapy, chemotherapy, targeted therapy, or any investigational therapy for pancreatic cancer.

• Demonstrate adequate organ function as defined in the table below; all screening labs to be obtained within 28 days prior to registration.

• Hematological

• Absolute Neutrophil Count (ANC) = 1.5 K/mm3

• Hemoglobin (Hgb) = 8.0 g/dL

• Platelets =100,000/mm3

• Renal

---Calculated creatinine clearance = 30 cc/min using the Cockcroft-Gault formula

• Hepatic

• Bilirubin = 1.5 × upper limit of normal (ULN)

• Aspartate aminotransferase (AST) = 3 × ULN

• Alanine aminotransferase (ALT) = 3 × ULN

• Females of childbearing potential must have a negative pregnancy test (serum or urine) within 3 days prior to registration. See the protocol for definition of childbearing potential.

• Females of childbearing potential must be willing to abstain from vaginal intercourse or use an effective method(s) of contraception from the time of informed consent, during the study, and for 6 months after the last dose of study drug(s). Males must be willing to abstain from vaginal intercourse or to use an effective method(s) of contraception from initiation of treatment, during the study, and for 3 months after the last dose of study drug(s). See also the protocol (contraception).

• As determined by the enrolling physician or protocol designee, ability of the subject to understand and comply with study procedures for the entire length of the study

• HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of registration are eligible for this trial.

• Patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated. Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, the HCV viral load must be undetectable to be eligible for this trial.

Exclusion Criteria:

• Evidence of distant metastasis

• Patients with an electrical implantable device in the torso. Examples of electrical implanted medical devices include spinal cord stimulators, vagus nerve stimulators, pacemakers, and defibrillators.

• History of significant uncontrolled cardiovascular disease. Significant cardiac disease includes second/third degree heart block; significant ischemic heart disease; poorly controlled hypertension; congestive heart failure of the New York Heart Association (NYHA) Class II or worse (slight limitation of physical activity; comfortable at rest, but ordinary activity results in fatigue, palpitation or dyspnea).

• History of arrhythmia that is symptomatic or requires treatment. Patients with atrial fibrillation or flutter controlled by medication are not excluded from participation in the trial -Known allergy to medical adhesives or conductive hydrogel (gel used on electrocardiogram (ECG) stickers or transcutaneous electrical nerve stimulation (TENS) electrodes).

• Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the mother is being treated on study).

• Patients with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen are not eligible for this trial.

• Patient has any other concurrent severe and/or uncontrolled medical condition that would, in the investigator's judgment, cause unacceptable safety risks, contraindicate patient participation in the clinical study or compromise compliance with the protocol: (e.g., chronic pancreatitis, chronic active hepatitis, active untreated or uncontrolled fungal, bacterial or viral infections, etc.)

• No prior malignancy is allowed except for adequately treated basal (or squamous cell) skin cancer, in situ cervical cancer or other cancer for which the patient has been disease and treatment-free for two years.

• Patient is unwilling or unable to comply with study procedures.

Related Conditions & MeSH terms

• Adenocarcinoma
• Pancreatic Adenocarcinoma
• Resectable Pancreatic Cancer

Intervention

Drug:
• Nab paclitaxel
125 mg/m^2 IV over 30 minutes or per site standard on days 1, 8, and 15 of a 28 day cycle
• Gemcitabine
1000 mg/m^2 IV over 30 minutes or per site standard on days 1, 8, and 15 of a 28 day cycle

Device:
• NovoTTF-200T(P)
Worn > 18 hr /day starting C1D1 until completion of cycle 3

Locations

Country	Name	City	State
United States	Ohio State University Comprehensive Cancer Center	Columbus	Ohio

Sponsors (3)

Lead Sponsor	Collaborator
Ashish Manne	NovoCure GmbH, Ohio State University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	2 Year Overall Survival (OS)	Determine the two-year OS rate. Two-year (2-Y) OS will be calculated as the percentage of patients who remain alive at the 2 year mark from the registration date.	2 years
Primary	Rate of Resection	Determine the rate of resection following the neoadjuvant treatment with TTFields in combination with chemotherapy. Resectability rate will be calculated as the proportion of evaluable patients undergoing R0 or R1 resection following the neoadjuvant segment of therapy.	4 years
Secondary	Assess adverse events	Assess frequency and severity of adverse events when TTFields is added to gemcitabine and nab-paclitaxel chemotherapy using CTCAE v5 criteria. Adverse Events (AE): AEs and the maximum grade for each type of adverse events will be summarized for each patient separately for the following three periods: During perioperative therapy; Complications during surgery and post-operative period for 30 days; During adjuvant therapy	3 months, 5 months, and 10 months
Secondary	Overall Response Rate (ORR)	Determine ORR. Overall response rate will include confirmed complete response (CR) + confirmed partial response (PR) and will be determined as per RECIST v1.1.	4 years
Secondary	Post Resection Disease Free Survival (DFS)	Estimate the post resection DFS. DFS will be estimated in patients undergoing resection and will be defined as the date of resection to the date of first documentation of recurrence (loco-regional or distant) or death due to any cause.	4 years
Secondary	Overall Survival (OS)	Estimate the median OS is defined as the time from initiation of therapy to death from any cause. OS will be assessed from date of registration till death from any cause on an intention to treat basis.	4 years
Secondary	Rate of Major Histological Response	Assess the patterns and rate of major histological response.Pathologic response will be evaluated after the patient has had surgery, and will be based on local pathology review of the resected surgical specimen, according to the following (Treatment effect assessment will be per "College of American Pathology Protocol for the Examination of Specimens From Patients With Carcinoma of the Exocrine Pancreas"); Tumor Regression Grade: 0: Complete response - no residual tumor; 1: Moderate response - minimal residual cancer (single cells or small groups of cancer cells); 2: Minimal response - residual cancer outgrown by fibrosis; 3: Poor or no response - no definite response identified (minimal or no tumor kill; Extensive residual cancer)	4 years
Secondary	Patterns of Recurrence	Describe the patterns of recurrence. Pattern of recurrence will be assessed for patients undergoing resection and will be categorized into local vs distant. Loco-regional recurrence will be defined as any evidence of new disease within the pancreatic tumor bed based on surveillance scans. The pancreatic tumor bed includes: Superior mesenteric artery and vein lymph nodes; Lymph nodes in porta hepatis (bile duct, portal vein, hepatic artery lymph nodes); Lymph nodes around left renal vein, inferior vena cava or aorta; Celiac axis lymph nodes	4 years
Secondary	Time to Locoregional Recurrence (TLR)	Evaluate TLR. TLR is defined as the time from the date of registration to the date of locoregional recurrence after resection.	4 years
Secondary	Time to Distant Metastases (TDM)	Evaluate TDM. Time to Distant Metastases (TDM): TDM is defined as the time from the date of registration to the date of metastases prior to surgery, metastases detected during surgery, or distant recurrence after resection.	4 years
Secondary	Chemotherapy relative dose intensity	Chemotherapy relative dose intensity delivered per agent is defined as the total cumulative dose (both perioperative and adjuvant) the patient received divided by total dose planned per protocol, times 100%.	4 years
Secondary	TTFields Compliance Rate	Evaluate compliance with TTFields. The device will be inspected either by the investigator or by a Novocure representative on a monthly basis to assess patient compliance with therapy. Average number of daily hours will be calculated.	4 years